Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Edecesertib - Gilead Sciences

Next Previous
Drug Profile

Edecesertib - Gilead Sciences

Alternative Names: GS-5718; Interleukin-1 receptor-associated kinase 4 inhibitor - Gilead Sciences

Latest Information Update: 24 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Class Anti-inflammatories; Antirheumatics; Skin disorder therapies; Small molecules
  • Mechanism of Action IRAK4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cutaneous lupus erythematosus; Systemic lupus erythematosus
  • No development reported Inflammation
  • Discontinued Inflammatory bowel diseases; Rheumatoid arthritis

Most Recent Events

  • 14 Jan 2026 Gilead Sciences terminates Phase-II COSMIC clinical trials in Cutaneous lupus erythematosus (In adults, In the elderly) in Spain, Germany (PO) due to sponsor's decision (NCT05629208)
  • 28 Oct 2024 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in Australia (PO, Tablet)
  • 11 Aug 2023 Chemical structure information added

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top